EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Cardiometabolic Parameters 3 Years After Switch to Dolutegravir/Lamivudine vs Maintenance of Tenofovir Alafenamide–Based Regimens

Rachel L Batterham, Nuria Espinosa, Christine Katlama, Mehri McKellar, Stefan Scholten, Don E Smith, Mounir Ait-Khaled, Nisha George, Jonathan Wright, Lori A Gordon, Riya Moodley, Brian Wynne und 1 weitere

Open Forum Infectious Diseases · 01.07.2023 · 10 (7)

DOI: 10.1093/ofid/ofad359 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Open Forum Infectious Diseases, online erschienen am 12.07.2023. Verfasst von Rachel L Batterham und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Centre for Obesity Research, University College London, London, UK. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: ViiV Healthcare.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cardiometabolic outcomes were investigated 3 years after switching to the 2-drug regimen dolutegravir/lamivudine (DTG/3TC) vs continuing 3-/4-drug tenofovir alafenamide (TAF)–based regimens in a multicenter phase 3 noninferiority study based on an open-label randomized design.

Method

Adults with virologically suppressed HIV-1 switched to once-daily DTG/3TC (n = 369) or continued TAF-based regimens (n = 372). Cardiometabolic health parameters were assessed through week 144 via mixed-model repeated measures or logistic regression analyses, adjusting for baseline variables.

Results

At week 144, 13% (42/316) of the DTG/3TC group and 12% (37/303) of the TAF-based regimen group had ≥10% weight gain from baseline (adjusted odds ratio, 1.11; 95% CI, .68–1.80). Adjusted change from baseline in serum leptin, a surrogate marker of adiposity, was similar between groups (treatment ratio, 1.00; 95% CI, .89–1.13). The lipid profile generally favored DTG/3TC in the baseline boosted subgroup. Adjusted odds revealed no clinically meaningful differences between groups: homeostatic model assessment of insulin resistance ≥2 (adjusted odds ratio, 0.79; 95% CI, .50–1.26), metabolic syndrome (International Diabetes Federation criteria, 0.99; .59–1.68), hepatic fibrosis (fibrosis-4 index score ≥1.45, 1.39; .63–3.06), and coronary artery disease risk (Framingham risk score ≥10%, 0.92; .56–1.49). Baseline variables and characteristics associated with odds of each cardiometabolic parameter outcome were consistent with known risk factors, including age, sex, race, and some disease characteristics.

Conclusions

Cardiometabolic health 3 years after switching to DTG/3TC was comparable to that for individuals continuing TAF-based regimens, further supporting DTG/3TC as a robust switch option with a stable metabolic profile.

Trial registration

ClinicalTrials.gov NCT03446573

Schlagwörter

Stichwörter der Autor:innen

2-drug regimencardiometabolic healthinsulin resistanceleptinweight

Autor:innen und Institutionen

  • Department of Medicine, Centre for Obesity Research, University College London, London, UK.
  • National Institute of Health Research, University College London Hospitals Biomedical Research Centre, London, UK.
  • Hospital Universitario Virgen del Rocío, Sevilla, Andalucía, Spain.
  • Service de Maladies Infectieuses et Tropicales, AP-HP, Hôpital Pitié-Salpêtrière, INSERM-Sorbonne Universités, Paris, France.
  • Department of Medicine, School of Medicine, Duke University, Durham, North Carolina, USA.
  • Praxis Hohenstaufenring, Cologne, Germany.

Förderung

  • ViiV Healthcare

Zitieren

APA

Batterham, R. L., Espinosa, N., Katlama, C., McKellar, M., Scholten, S., Smith, D. E., Ait-Khaled, M., George, N., Wright, J., Gordon, L. A., Moodley, R., Wynne, B., & van Wyk, J. (2023). Cardiometabolic Parameters 3 Years After Switch to Dolutegravir/Lamivudine vs Maintenance of Tenofovir Alafenamide–Based Regimens. Open Forum Infectious Diseases, 10(7). https://doi.org/10.1093/ofid/ofad359

Vancouver

Batterham RL, Espinosa N, Katlama C, McKellar M, Scholten S, Smith DE, et al. Cardiometabolic Parameters 3 Years After Switch to Dolutegravir/Lamivudine vs Maintenance of Tenofovir Alafenamide–Based Regimens. Open Forum Infectious Diseases. 2023;10(7). doi:10.1093/ofid/ofad359

BibTeX
@article{Batterham2023,
  author = {Batterham, Rachel L and Espinosa, Nuria and Katlama, Christine and McKellar, Mehri and Scholten, Stefan and Smith, Don E and Ait-Khaled, Mounir and George, Nisha and Wright, Jonathan and Gordon, Lori A and Moodley, Riya and Wynne, Brian and van Wyk, Jean},
  title = {Cardiometabolic Parameters 3 Years After Switch to Dolutegravir/Lamivudine vs Maintenance of Tenofovir Alafenamide–Based Regimens},
  journal = {Open Forum Infectious Diseases},
  year = {2023},
  volume = {10},
  number = {7},
  doi = {10.1093/ofid/ofad359}
}
Kostenlos starten →